Basit öğe kaydını göster

dc.contributor.authorRahatlı, Samed
dc.contributor.authorDizdar, Ömer
dc.contributor.authorKüçüköztaş, Nadire
dc.contributor.authorOğuz, Arzu
dc.contributor.authorYalçın, Selim
dc.contributor.authorÖzen, Özlem
dc.contributor.authorHaberal Reyhan, Nihan
dc.contributor.authorTarhan, Çağla
dc.contributor.authorYıldız, Ferah
dc.contributor.authorDursun, Polat
dc.contributor.authorAltundağ, Özden
dc.contributor.authorAyhan, Ali
dc.date.accessioned2020-02-05T07:37:13Z
dc.date.available2020-02-05T07:37:13Z
dc.date.issued2014
dc.identifier.issn1513-7368
dc.identifier.urihttps://doi.org/10.7314/APJCP.2014.15.9.3891
dc.identifier.urihttp://hdl.handle.net/11655/22028
dc.description.abstractBackground: Most patients with endometrial cancer have stage I disease. Adjuvant therapy in stage IB (formerly IC) endometrial cancer is controversial, treatment options including observation or brachytherapy/radiotherapy in grade 1-3 patients with or without chemotherapy. The purpose of this study was to assess the outcomes of our patients with stage IB endometrioid endometrial cancer. Materials and Methods: Sixty two patients with stage IB endometrial cancer and endometrioid histology were retrospectively evaluated. All patients were initially treated surgically by the same surgeon with comprehensive staging, i.e. total abdominal hysterectomy, bilateral salphingooopherectomy, bilateral pelvic and paraaortic lymph node dissection and omentectomy. Adjuvant radiotherapy was discussed with patients and utilized by those who accepted. Adjuvant chemotherapy was not given to any of the patients. Results: Median age was 62 (range, 42-95). Ninety percent of the patients had grade 1-2 disease. Thirteen patients (21%) received intra vaginal brachytherapy (IVBT) and one received whole pelvic radiotherapy (WPRT). Median follow-up time was 46 months (range, 9-77 months). Three patients experienced recurrence (4.8%), two of them died on follow-up and one was still alive at last visit. Two patients with recurrence had FIGO grade 2 tumors and one had a grade 3 tumor. Two patients (3.2%) died without evidence of recurrent disease. Relapse free survival at 5 years was 94.4% and overall survival was 93.1%. Conclusions: Patients with stage IB disease in our study demonstrated relatively low recurrence rates with this stage of endometrial cancer.tr_TR
dc.language.isoentr_TR
dc.publisherAsian Pacific Organization Cancer Preventiontr_TR
dc.relation.isversionof10.7314/APJCP.2014.15.9.3891tr_TR
dc.rightsinfo:eu-repo/semantics/openAccesstr_TR
dc.subjectOncologytr_TR
dc.subject.lcshKansertr_TR
dc.titleGood Outcomes Of Patients With Stage Ib Endometrial Cancer With Surgery Alonetr_TR
dc.typeinfo:eu-repo/semantics/articletr_TR
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalAsian Pacific Journal Of Cancer Preventiontr_TR
dc.contributor.departmentPrevantif Onkolojitr_TR
dc.identifier.volume15tr_TR
dc.identifier.issue9tr_TR
dc.identifier.startpage3891tr_TR
dc.identifier.endpage3893tr_TR
dc.description.indexWoStr_TR
dc.description.indexScopustr_TR
dc.fundingYoktr_TR


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster